Logo

Silence

Silence Therapeutics Inks Deal to Access Genomics England Database

Silence Therapeutics aims to use the database to help identify new drug targets, as well as for patient recruitment and stratification in clinical trials.

Silence Takes Aim at mRNA Therapeutics as RNAi Cancer Drug Advances
Premium

According to its CEO, Silence is aiming to expand into a "full-functioning biotech" with more than just a single product.

Silence Puts Sepsis Program on Backburner as it Advances Cancer Drug
Premium

NEW YORK (GenomeWeb) – Silence Therapeutics this month disclosed that it was ending its work with investigational sepsis drug Atu112 amid disappointing results in preclinical testing.

Silence Collaborators Publish Animal Data on siRNA Drug in Sepsis
Premium

NEW YORK (GenomeWeb) – Silence Therapeutics this week announced the publication of preclinical data showing that its acute lung injury drug Atu111 could reduce the severity of sepsis-related illness and improve survival in mice.

Silence Completes Patient Enrollment in Cancer Drug Study
Premium

NEW YORK (GenomeWeb) – Silence Therapeutics this week announced that it has completed patient recruitment for a Phase IIa trial of its siRNA-based cancer drug Atu027.
Jul 17, 2014

Key RNAi Drugs in the Clinic: July 2014
Premium

Nov 21, 2013

Silence Oncology Drug Candidate to be Tested in Head and Neck Cancer
Premium

Nov 21, 2013

People in the News: Jerry Randall, Simon Sturge, Annie Cheng, Klaus Geise, Jorg Kaufmann
Premium

Jun 20, 2013

Silence Cancer Drug Advances into Phase IIa Portion of Clinical Study
Premium

May 30, 2013

Silence Starts Phase Ib/IIa Trial of Cancer Drug as It Looks to Balance Pipeline
Premium

Apr 11, 2013

Silence Plans $28.6M Stock Sale to Fund Expansion of Staff, Pipeline
Premium

Mar 21, 2013

After Losing Another CEO, Silence Management Aims to Fill in Corporate Gaps
Premium

Mar 7, 2013

Silence Cleared to Test Cancer Drug in Pancreatic Cancer
Premium

Jan 24, 2013

IP Update: Recent Patents, Patent Applications Awarded to CalTech, Alnylam, Silence, and More
Premium

Jan 3, 2013

People: Michael Khan
Premium

Oct 11, 2012

Silence Reports Higher 1H Loss on Special Charge
Premium

Sep 20, 2012

People in the News: Michael Khan
Premium

Sep 13, 2012

Silence Says Lung Injury Drug Shows Promise in Animal Study
Premium

Aug 23, 2012

Silence Inks Delivery Tech Evaluation Deal with Mireven
Premium

Aug 2, 2012

Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
Premium

Jul 12, 2012

Silence Looks to Raise $8.8M in Share Issuance, Return Zamore IP Rights to UMass
Premium

Jun 7, 2012

Silence Releases New Data on Cancer Drug, In Talks for Needed Investment
Premium

Mar 22, 2012

Silence Says Cash Runway Ends in Q3, Directors Have 'Uncertainty' About Additional Fundraising
Premium

Mar 22, 2012

People in the News: Detlef Schuppan, Massimo Pinzani
Premium

Mar 15, 2012

Silence Responds to Alnylam European Patent Claims
Premium

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.